Biomarker Technology Platforms for Cancer Diagnoses and Therapies

Until superior therapeutic treatments are developed to prevent, treat and cure cancer, the best means of reducing mortality and morbidity in a disease this complex is early detection and diagnosis. In the major solid cancer types such as lung, breast, colon and prostate, long-term survival rates drop precipitously once metastatis has occurred. The case is clear for development of biomarkers for early detection and screening tests for diseases such as breast, colon, ovarian and lung cancer. In addition, diagnostic measurement of cancer disease progression is essential to successful disease management. For these reasons, development of new and effective biomarkers for cancer detection and diagnosis is central to the cancer problem. The use of nucleic acid biomarker diagnostics have begun to answer these questions. Protein biomarkers are also useful. The purpose of this TriMark Publications report is to describe the specific segment of the cancer diagnostics market which develops new biomarker technology platforms for diagnosing and treating cancer. Biomarkers are useful in following the course of cancer and evaluating which therapeutic regimes are most effective for a particular type of cancer, as well as determining long-term susceptibility to cancer or recurrence. This study particularly examines those clinical measurement devices, and their reagents and supplies, which are meant to be used in hospitals, clinics, commercial laboratories and doctor’s offices to diagnose and monitor cancer. The examination also provides an in-depth discussion of the application of biomarkers in developing novel targeted cancer therapeutics, their predication response and efficacy, as well as their use in diagnosis of cancer.
1. Overview
 1.1 Statement of Report
 1.2 About This Report
 1.3 Scope of the Report
 1.4 Objectives
 1.5 Methodology
 1.6 Executive Summary
 
 2. Introduction to Cancer Biology and the Diagnostic Industry
 2.1 Biomarkers
 2.1.1 The Biomarker Market Drivers
 2.1.1.1 The Sector
 2.1.1.2 The Critical Path Opportunities
 2.1.1.3 The Capital Markets
 2.2 Cancer Detection and Treatment with Biomarkers
 2.2.1 The Problem
 2.3 Cancer: The Disease
 2.3.1 Metastasis
 2.3.2 Demographics and Statistics of Cancer
 2.4 Drivers of the Biotech and Diagnostics Industry
 2.4.1 Venture Funding of Biotech Sector
 2.4.2 Technological Innovation
 2.4.3 Government Funding
 2.4.4 Pharmaceutical Development and Bioanalytical Services
 2.4.5 The War on Cancer
 2.4.6 Current Oncology Drug Development
 2.5 Outlook for Tumor Markers
 2.6 Focus on Proteomics
 2.6.1 Scientific Background
 2.6.2 The Relationship between Proteins and Diseases
 2.6.3 Limitations of Existing Diagnostic Approaches
 2.6.4 Addressing the Heterogeneity of Cancer
 2.6.5 Validation of Biomarkers Through Proper Study Design
 2.6.6 Exploiting the Power of Mass Spectrometry to Improve Assay Specificity
 2.6.7 Creating and Maintaining a Multi-Disease Product Pipeline
 2.6.8 Partnerships for Developing Proteomic Biomarkers
 2.7 Epigenic Markers for Cancer
 2.8 Molecular Diagnostics Testing for Cancer
 2.9 Market Opportunities
 2.9.1 Industry Overview
 2.9.2 Medical Indications and Medically Useful Information
 2.9.3 Research Market
 2.9.4 Competition
 2.9.5 Diagnostic Services
 2.9.6 Clinical Image Analysis
 2.9.7 Research Imaging Market
 2.9.8 Genomic Disease Management and In Vitro Diagnostic Multivariate Index Assays (IVDMIA)
 2.9.9 Predictive Expression Profiles
For more information, please visit:
http://www.aarkstore.com/reports/Biomarker-Technology-Platforms-for-Cancer-Diagnoses-and-Therapies-1299.html
Or email us at press@aarkstore.com or call +919272852585